Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

Other Questions

Back to Help Center

For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Do you need me to provide you with passwords for the hospital accounts?

No, we don’t need the password to associate the doctors and hospital. Once we register it, the password will be sent to the corresponding emails.

How do vets report back the outcomes to feed back into the AI model? Is this something that can be easily done via the Vet portal?

We usually send you an email asking for patient records about 3-6 months after you receive the final ImpriMed report. Once we receive the record, we input the data into the AI Models, it is not yet something that can be submitted on the Vet Portal.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

What is the simulated dosing for a certain drug? MTD(maximum tolerated dosing) or metronomic?

Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.